Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 02, 2023

Patient-Reported Outcomes and Hospitalization Data in Patients With HER2-Positive MBC Receiving Trastuzumab Deruxtecan vs Trastuzumab Emtansine

Annals of Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase 3 DESTINY-Breast03 study
Ann. Oncol 2023 May 11;[EPub Ahead of Print], G Curigliano, K Dunton, M Rosenlund, M Janek, J Cathcart, Y Liu, PA Fasching, H Iwata

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading